Paresh N. Soni

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

Harold Bays, Christie M. Ballantyne, John J.P. Kastelein et al. · The American Journal of Cardiology · 2011 · 345 citations

Metabolic Syndrome, Lipid Disorder, Cardiovascular Disease +7

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

Christie M. Ballantyne, Harold Bays, John J.P. Kastelein et al. · The American Journal of Cardiology · 2012 · 331 citations

Metabolic Syndrome, Lipid Disorder, Cardiovascular Disease +8

Rationale and design of <scp>REDUCE‐IT</scp>: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Deepak L. Bhatt, Philippe Gabríel Steg, Eliot A. Brinton et al. · Clinical Cardiology · 2017 · 177 citations · Full text

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

Harold Bays, Christie M. Ballantyne, Rene A. Braeckman et al. · American Journal of Cardiovascular Drugs · 2013 · 138 citations · Full text

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Harold Bays, Rene A. Braeckman, Christie M. Ballantyne et al. · Journal of clinical lipidology · 2012 · 91 citations

Metabolic Syndrome, Nutrition, Omega-3 Fatty Acid +6